Primary aldosteronism
Conditions
Interventions
None listed
Sponsors
Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan
Institute of Science Tokyo hospital, Affiliated Hospital of Chongqing Medical University, Monash University, and Hudson Institute of Medical Research
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who were diagnosed with primary aldosteronism and essential hypertension at Nihon University Itabashi Hospital (January 1, 2006 - January 1, 2030). 2. Patients who were diagnosed with primary aldosteronism and essential hypertension at Institute of Science Tokyo Hospital, Affiliated Hospital of Chongqing Medical University, Monash University, and Hudson Institute of Medical Research (January 1, 2006 - January 1, 2030).
Exclusion criteria
Exclusion criteria: Patients who refused to participate in this study and the investigator determined to be unsuitable for study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| age, gender, blood pressure, BMI, blood tests (serum biochemistry test, daily fluctuation of hormones, etc.), urinalysis, confirmatory tests(captopril challenge test, furosemide and upright posture test, saline infusion test), contrast CT examination, adrenal vein sampling, portable polysomnography, ankle brachial pressure index, cardiac ultrasound, abdominal ultrasound, carotid ultrasound | — |
Secondary
| Measure | Time frame |
|---|---|
| Proteins presumed to be involved in primary aldosteronism, comprehensive protein profiling using omics platforms, and non-coding RNA | — |
Countries
Japan,Asia(except Japan),Australia
Contacts
Public ContactHiroki Kobayashi
Nihon University School of Medicine Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine
Outcome results
None listed